Arnab K. Chatterjee

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

The paper identifies and optimizes imidazothiazole carboxamides as anti-tuberculosis agents, showing activity against drug-resistant strains and improved potency in analogs.

The paper identifies a novel Rv1625c agonist chemotype with antitubercular activity, optimizing its structure to improve potency and bioavailability.

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

This study investigates the antiviral activity and mechanism of 4'-fluoroadenosine against viral and host polymerases, showing broad-spectrum inhibition and potential for drug development.

This study identifies divergent resistance mechanisms in Plasmodium HSP90 inhibitors despite shared binding sites, showing that enhanced binding can paradoxically correlate with resistance.

This study identifies sCMF231, a small molecule that activates YAP by inhibiting FUBI-mediated fubylation of Annexin A2, thereby enhancing YAP transcriptional activity.

The paper identifies 44 compounds with >50% inhibitory effects against Toxoplasma gondii bradyzoites using a high-throughput screen and characterizes one compound's activity.

This paper identifies mCMQ069, a novel antimalarial with potential for single-dose cure and one-month chemoprevention, showing improved pharmacokinetic properties over KAF156.

This paper describes new bicyclic pyrrolidine inhibitors of Toxoplasma gondii PheRS with improved potency, selectivity, and brain exposure compared to previous azetidine-based inhibitors.

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.